SHRUS 1001: A two-part Phase I, open label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy

September 15, 2017
https://clinicaltrials.gov/ct2/show/NCT02500199
Solid Tumors
Principal Investigator: Ding Wang, MD
Solid Tumors
Accepting Participants
(313)916-1784